Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla.
from Reuters: Health News https://reut.rs/2MGE8Yw
Friday, February 1, 2019
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment